EUVIMEDEUVIMED entdecken
Open Access

Venous Thromboembolism in Total Hip and Total Knee Arthroplasty

Samantha J Simon, Rushad Patell, Jeffrey I Zwicker, Dhruv S Kazi, Brian L Hollenbeck

JAMA Network Open · 01.12.2023 · 6 (12) · e2345883

DOI: 10.1001/jamanetworkopen.2023.45883 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 01.12.2023. Verfasst von Samantha J Simon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Department, New England Baptist Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Venous Thromboembolism, Arthroplasty, Replacement, Knee. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The optimal pharmacologic thromboprophylaxis agent after total hip and total knee arthroplasty is uncertain and consensus is lacking. Quantifying the risk of postoperative venous thromboembolism (VTE) and bleeding and evaluating comparative effectiveness and safety of the thromboprophylaxis strategies can inform care.

Objective

To quantify risk factors for postoperative VTE and bleeding and compare patient outcomes among pharmacological thromboprophylaxis agents used after total hip and knee arthroplasty. Design, Setting, and Participants This retrospective cohort study used data from a large health care claims database. Participants included patients in the United States with hip or knee arthroplasty and continuous insurance enrollment 3 months prior to and following their surgical procedure. Patients were excluded if they received anticoagulation before surgery, received no postsurgical pharmacological thromboprophylaxis, or had multiple postsurgery thromboprophylactic agents. In a propensity-matched analysis, patients receiving a direct oral anticoagulant (DOAC) were matched with those receiving aspirin. Exposures Aspirin, apixaban, rivaroxaban, enoxaparin, or warfarin. Main Outcomes and Measures The primary outcome was 30-day cumulative incidence of postdischarge VTE. Other outcomes included postdischarge bleeding.

Results

Among 29 264 patients included in the final cohort, 17 040 (58.2%) were female, 27 897 (95.2%) had inpatient admissions with median (IQR) length of stay of 2 (1-2) days, 10 948 (37.4%) underwent total hip arthroplasty, 18 316 (62.6%) underwent total knee arthroplasty; and median (IQR) age was 59 (55-63) years. At 30 days, cumulative incidence of VTE was 1.19% (95% CI, 1.06%-1.32%) and cumulative incidence of bleeding was 3.43% (95% CI, 3.22%-3.64%). In the multivariate analysis, leading risk factors associated with increased VTE risk included prior VTE history (odds ratio [OR], 5.94 [95% CI, 4.29-8.24]), a hereditary hypercoagulable state (OR, 2.64 [95% CI, 1.32-5.28]), knee arthroplasty (OR, 1.65 [95% CI, 1.29-2.10]), and male sex (OR, 1.34 [95% CI, 1.08-1.67]). In a propensity-matched cohort of 7844 DOAC-aspirin pairs, there was no significant difference in the risk of VTE in the first 30 days after the surgical procedure (OR, 1.14 [95% CI, 0.82-1.59]), but postoperative bleeding was more frequent in patients receiving DOACs (OR, 1.36 [95% CI, 1.13-1.62]). Conclusions and Relevance In this cohort study of patients who underwent total hip or total knee arthroplasty, underlying patient risk factors, but not choice of aspirin or DOAC, were associated with postsurgical VTE. Postoperative bleeding rates were lower in patients prescribed aspirin. These results suggest that thromboprophylaxis strategies should be patient-centric and tailored to individual risk of thrombosis and bleeding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismArthroplasty, Replacement, KneeHumansMaleFemaleUnited StatesMiddle AgedAnticoagulantsCohort StudiesRetrospective StudiesAftercarePatient DischargeAspirinPostoperative Hemorrhage

Substanzen

AnticoagulantsAspirin

Autor:innen und Institutionen

  • Research Department, New England Baptist Hospital, Boston, Massachusetts.
  • Division of Hematology and Hematologic Malignancies, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Harvard Medical School, Boston, Massachusetts.
  • Hematology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Förderung

  • NCI NIH HHS

Zitieren

APA

Simon, S. J., Patell, R., Zwicker, J. I., Kazi, D. S., & Hollenbeck, B. L. (2023). Venous Thromboembolism in Total Hip and Total Knee Arthroplasty. JAMA Network Open, 6(12), e2345883. https://doi.org/10.1001/jamanetworkopen.2023.45883

Vancouver

Simon SJ, Patell R, Zwicker JI, Kazi DS, Hollenbeck BL. Venous Thromboembolism in Total Hip and Total Knee Arthroplasty. JAMA Network Open. 2023;6(12):e2345883. doi:10.1001/jamanetworkopen.2023.45883

BibTeX
@article{Simon2023,
  author = {Simon, Samantha J and Patell, Rushad and Zwicker, Jeffrey I and Kazi, Dhruv S and Hollenbeck, Brian L},
  title = {Venous Thromboembolism in Total Hip and Total Knee Arthroplasty},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {12},
  pages = {e2345883},
  doi = {10.1001/jamanetworkopen.2023.45883}
}
Kostenlos starten →